Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00556530 · ClinicalTrials.gov registry record
Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome
A clinical trial of DiGeorge Syndrome and 22q11.2 Deletion Syndrome, sponsored by Albert Einstein College of Medicine.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT00556530 is a study of DiGeorge Syndrome and 22q11.2 Deletion Syndrome that is actively recruiting participants, run by Albert Einstein College of Medicine. The registered enrollment target is 1,000 participants, above the 203-participant average among 4 other DiGeorge Syndrome trials with a reported enrollment target (393% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00556530, a study of DiGeorge Syndrome and 22q11.2 Deletion Syndrome, is actively recruiting participants, sponsored by Albert Einstein College of Medicine.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
22q11.2 deletion syndrome is a genetic disorder that can cause heart defects, facial abnormalities, and developmental and learning disabilities. The severity of the disorder can vary widely among people. This study will analyze DNA from people with 22q11.2 deletion syndrome to identify genetic variations that may affect the severity of the disorder.
Conditions Studied
Study Locations (1)
New York
- Albert Einstein College of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2016-07 |
| Est. Completion | 2029-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00556530
The ClinicalTrials.gov registry entry for NCT00556530 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 203-participant average among 4 other DiGeorge Syndrome trials with a reported enrollment target (393% higher). The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with DiGeorge Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT00556530 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00556530 about?
NCT00556530 is a clinical study titled "Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome". 22q11.2 deletion syndrome is a genetic disorder that can cause heart defects, facial abnormalities, and developmental and learning disabilities. The severity of the disorder can vary widely among people. This study will analyze DNA from people with 22q11.2 deletion syndrome to identify genetic varia...
What is the current status of trial NCT00556530?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2016-07. Estimated completion is 2029-06.
What conditions does trial NCT00556530 study?
This clinical trial studies the following conditions: DiGeorge Syndrome, 22q11.2 Deletion Syndrome.
Who is sponsoring clinical trial NCT00556530?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00556530 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for DiGeorge Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)
RECRUITING · Phase 2
-
Immune Disorder HSCT Protocol
ACTIVE NOT RECRUITING · Phase 2
-
Thymus Transplantation Dose in DiGeorge #932
COMPLETED · Phase 2
-
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.